<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35328829</PMID><DateCompleted><Year>2022</Year><Month>04</Month><Day>08</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>08</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1422-0067</ISSN><JournalIssue CitedMedium="Internet"><Volume>23</Volume><Issue>6</Issue><PubDate><Year>2022</Year><Month>Mar</Month><Day>21</Day></PubDate></JournalIssue><Title>International journal of molecular sciences</Title><ISOAbbreviation>Int J Mol Sci</ISOAbbreviation></Journal><ArticleTitle>Therapeutic Treatment of Superoxide Dismutase 1 (G93A) Amyotrophic Lateral Sclerosis Model Mice with Medical Ozone Decelerates Trigeminal Motor Neuron Degeneration, Attenuates Microglial Proliferation, and Preserves Monocyte Levels in Mesenteric Lymph Nodes.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">3403</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/ijms23063403</ELocationID><Abstract><AbstractText>Amyotrophic lateral sclerosis (ALS) is an incurable and lethal neurodegenerative disease in which progressive motor neuron loss and associated inflammation represent major pathology hallmarks. Both the prevention of neuronal loss and neuro-destructive inflammation are still unmet challenges. Medical ozone, an ozonized oxygen mixture (O<sub>3</sub>/O<sub>2</sub>), has been shown to elicit profound immunomodulatory effects in peripheral organs, and beneficial effects in the aging brain. We investigated, in a preclinical drug testing approach, the therapeutic potential of a five-day O<sub>3</sub>/O<sub>2</sub><i>i.p</i>. treatment regime at the beginning of the symptomatic disease phase in the superoxide dismutase (SOD1<sup>G93A</sup>) ALS mouse model. Clinical assessment of SOD1<sup>G93A</sup> mice revealed no benefit of medical ozone treatment over sham with respect to gross body weight, motor performance, disease duration, or survival. In the brainstem of end stage SOD1<sup>G93A</sup> mice, however, neurodegeneration was found decelerated, and SOD1-related vacuolization was reduced in the motor trigeminal nucleus in the O<sub>3</sub>/O<sub>2</sub> treatment group when compared to sham-treated mice. In addition, microglia proliferation was less pronounced in the brainstem, while the hypertrophy of astroglia remained largely unaffected. Finally, monocyte numbers were reduced in the blood, spleen, and mesenteric lymph nodes at postnatal day 60 in SOD1<sup>G93A</sup> mice. A further decrease in monocyte numbers seen in mesenteric lymph nodes from sham-treated SOD1<sup>G93A</sup> mice at an advanced disease stage, however, was prevented by medical ozone treatment. Collectively, our study revealed a select neuroprotective and possibly anti-inflammatory capacity for medical ozone when applied as a therapeutic agent in SOD1<sup>G93A</sup> ALS mice.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bette</LastName><ForeName>Michael</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-7336-8207</Identifier><AffiliationInfo><Affiliation>Institute of Anatomy and Cell Biology, Philipps-University, 35037 Marburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cors</LastName><ForeName>Eileen</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Institute of Anatomy and Cell Biology, Philipps-University, 35037 Marburg, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Mitochondrial Proteostasis, Max-Planck-Institute for Biology of Ageing, 50931 Cologne, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kresse</LastName><ForeName>Carolin</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Institute of Anatomy and Cell Biology, Philipps-University, 35037 Marburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sch&#xfc;tz</LastName><ForeName>Burkhard</ForeName><Initials>B</Initials><Identifier Source="ORCID">0000-0003-4473-1959</Identifier><AffiliationInfo><Affiliation>Institute of Anatomy and Cell Biology, Philipps-University, 35037 Marburg, Germany.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>Sc10/6</GrantID><Agency>Deutsche Gesellschaft f&#xfc;r Muskelkranke</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>03</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Int J Mol Sci</MedlineTA><NlmUniqueID>101092791</NlmUniqueID><ISSNLinking>1422-0067</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>66H7ZZK23N</RegistryNumber><NameOfSubstance UI="D010126">Ozone</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.15.1.1</RegistryNumber><NameOfSubstance UI="D013482">Superoxide Dismutase</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.15.1.1</RegistryNumber><NameOfSubstance UI="D000072105">Superoxide Dismutase-1</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D049109" MajorTopicYN="N">Cell Proliferation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007249" MajorTopicYN="N">Inflammation</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008198" MajorTopicYN="N">Lymph Nodes</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017628" MajorTopicYN="N">Microglia</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009000" MajorTopicYN="N">Monocytes</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009410" MajorTopicYN="N">Nerve Degeneration</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019636" MajorTopicYN="Y">Neurodegenerative Diseases</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010126" MajorTopicYN="Y">Ozone</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013482" MajorTopicYN="N">Superoxide Dismutase</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000072105" MajorTopicYN="N">Superoxide Dismutase-1</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">adaptive immune system</Keyword><Keyword MajorTopicYN="N">amyotrophic</Keyword><Keyword MajorTopicYN="N">monocyte</Keyword><Keyword MajorTopicYN="N">neurodegeneration</Keyword><Keyword MajorTopicYN="N">neuroinflammation</Keyword><Keyword MajorTopicYN="N">ozone</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>2</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>3</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>3</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>3</Month><Day>25</Day><Hour>1</Hour><Minute>8</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>3</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>4</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35328829</ArticleId><ArticleId IdType="pmc">PMC8950555</ArticleId><ArticleId IdType="doi">10.3390/ijms23063403</ArticleId><ArticleId IdType="pii">ijms23063403</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Kiernan M.C., Vucic S., Cheah B.C., Turner M.R., Eisen A., Hardiman O., Burrell J.R., Zoing M.C. Amyotrophic lateral sclerosis. Lancet. 2011;377:942&#x2013;955. doi: 10.1016/S0140-6736(10)61156-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(10)61156-7</ArticleId><ArticleId IdType="pubmed">21296405</ArticleId></ArticleIdList></Reference><Reference><Citation>Millecamps S., Boill&#xe9;e S., Le Ber I., Seilhean D., Teyssou E., Giraudeau M., Moigneu C., Vandenberghe N., Danel-Brunaud V., Corcia P., et al. Phenotype difference between ALS patients with expanded repeats in C9ORF72 and patients with mutations in other ALS-related genes. J. Med. Genet. 2012;49:258&#x2013;263. doi: 10.1136/jmedgenet-2011-100699.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jmedgenet-2011-100699</ArticleId><ArticleId IdType="pubmed">22499346</ArticleId></ArticleIdList></Reference><Reference><Citation>Chi&#xf2; A., Calvo A., Mazzini L., Cantello R., Mora G., Moglia C., Corrado L., D&#x2019;Alfonso S., Majounie E., Renton A., et al. Extensive genetics of ALS: A population-based study in Italy. Neurology. 2012;79:1983&#x2013;1989. doi: 10.1212/WNL.0b013e3182735d36.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0b013e3182735d36</ArticleId><ArticleId IdType="pmc">PMC3484987</ArticleId><ArticleId IdType="pubmed">23100398</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosen D.R., Siddique T., Patterson D., Figlewicz D.A., Sapp P., Hentati A., Donaldson D., Goto J., O&#x2019;Regan J.P., Deng H.X. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature. 1993;362:59&#x2013;62. doi: 10.1038/362059a0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/362059a0</ArticleId><ArticleId IdType="pubmed">8446170</ArticleId></ArticleIdList></Reference><Reference><Citation>Gurney M.E., Pu H., Chiu A.Y., Dal Canto M.C., Polchow C.Y., Alexander D.D., Caliendo J., Hentati A., Kwon Y.W., Deng H.X. Motor neuron degeneration in mice that express a human Cu, Zn superoxide dismutase mutation. Science. 1994;264:1772&#x2013;1775. doi: 10.1126/science.8209258.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.8209258</ArticleId><ArticleId IdType="pubmed">8209258</ArticleId></ArticleIdList></Reference><Reference><Citation>Mancuso R., Navarro X. Amyotrophic lateral sclerosis: Current perspectives from basic research to the clinic. Prog. Neurobiol. 2015;133:1&#x2013;26. doi: 10.1016/j.pneurobio.2015.07.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pneurobio.2015.07.004</ArticleId><ArticleId IdType="pubmed">26253783</ArticleId></ArticleIdList></Reference><Reference><Citation>Henkel J.S., Beers D.R., Wen S., Rivera A.L., Toennis K.M., Appel J.E., Zhao W., Moore D.H., Powell S.Z., Appel S.H. Regulatory T-lymphocytes mediate amyotrophic lateral sclerosis progression and survival. EMBO Mol. Med. 2013;5:64&#x2013;79. doi: 10.1002/emmm.201201544.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/emmm.201201544</ArticleId><ArticleId IdType="pmc">PMC3569654</ArticleId><ArticleId IdType="pubmed">23143995</ArticleId></ArticleIdList></Reference><Reference><Citation>Hooten K.G., Beers D.R., Zhao W., Appel S.H. Protective and Toxic Neuroinflammation in Amyotrophic Lateral Sclerosis. Neurotherapeutics. 2015;12:364&#x2013;375. doi: 10.1007/s13311-014-0329-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13311-014-0329-3</ArticleId><ArticleId IdType="pmc">PMC4404435</ArticleId><ArticleId IdType="pubmed">25567201</ArticleId></ArticleIdList></Reference><Reference><Citation>Geloso M.C., Corvino V., Marchese E., Serrano A., Michetti F., D&#x2019;Ambrosi N. The Dual Role of Microglia in ALS: Mechanisms and Therapeutic Approaches. Front. Aging. Neurosci. 2017;9:242. doi: 10.3389/fnagi.2017.00242.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnagi.2017.00242</ArticleId><ArticleId IdType="pmc">PMC5524666</ArticleId><ArticleId IdType="pubmed">28790913</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao W., Beers D.R., Appel S.H. Immune-mediated mechanisms in the pathoprogression of amyotrophic lateral sclerosis. J. Neuroimmune Pharmacol. 2013;8:888&#x2013;899. doi: 10.1007/s11481-013-9489-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11481-013-9489-x</ArticleId><ArticleId IdType="pmc">PMC4126425</ArticleId><ArticleId IdType="pubmed">23881705</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith N.L., Wilson A.L., Gandhi J., Vatsia S., Khan S.A. Ozone therapy: An overview of pharmacodynamics, current research, and clinical utility. Med. Gas. Res. 2017;7:212&#x2013;219. doi: 10.4103/2045-9912.215752.</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/2045-9912.215752</ArticleId><ArticleId IdType="pmc">PMC5674660</ArticleId><ArticleId IdType="pubmed">29152215</ArticleId></ArticleIdList></Reference><Reference><Citation>Kelly F.J., Mudway I., Krishna M.T., Holgate S.T. The free radical basis of air pollution: Focus on ozone. Respir. Med. 1995;89:647&#x2013;656. doi: 10.1016/0954-6111(95)90131-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0954-6111(95)90131-0</ArticleId><ArticleId IdType="pubmed">8570878</ArticleId></ArticleIdList></Reference><Reference><Citation>Viebahn-Haensler R., Le&#xf3;n Fern&#xe1;ndez O.S. Ozone in Medicine. The Low-Dose Ozone Concept and Its Basic Biochemical Mechanisms of Action in Chronic Inflammatory Diseases. Int. J. Mol. Sci. 2021;22:7890. doi: 10.3390/ijms22157890.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms22157890</ArticleId><ArticleId IdType="pmc">PMC8346137</ArticleId><ArticleId IdType="pubmed">34360655</ArticleId></ArticleIdList></Reference><Reference><Citation>Elkholy W.B., Al-Gholam M.A. Role of medical ozone in attenuating age-related changes in the rat cerebellum. Microscopy. 2018;67:214&#x2013;221. doi: 10.1093/jmicro/dfy017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jmicro/dfy017</ArticleId><ArticleId IdType="pubmed">29635467</ArticleId></ArticleIdList></Reference><Reference><Citation>El-Mehi A.E., Faried M.A. Controlled ozone therapy modulates the neurodegenerative changes in the frontal cortex of the aged albino rat. Ann. Anat. 2020;227:151428. doi: 10.1016/j.aanat.2019.151428.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.aanat.2019.151428</ArticleId><ArticleId IdType="pubmed">31610254</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin S.Y., Ma J., An J.X., Qian X.Y., Wang Y., Cope D.K., Williams J.P. Ozone Inhibits APP/A&#x3b2; Production and Improves Cognition in an APP/PS1 Transgenic Mouse Model. Neuroscience. 2019;418:110&#x2013;121. doi: 10.1016/j.neuroscience.2019.07.027.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuroscience.2019.07.027</ArticleId><ArticleId IdType="pubmed">31349006</ArticleId></ArticleIdList></Reference><Reference><Citation>Delgado-Roche L., Riera-Romo M., Mesta F., Hern&#xe1;ndez-Matos Y., Barrios J.M., Mart&#xed;nez-S&#xe1;nchez G., Al-Dalaien S.M. Medical ozone promotes Nrf2 phosphorylation reducing oxidative stress and pro-inflammatory cytokines in multiple sclerosis patients. Eur. J. Pharmacol. 2017;811:148&#x2013;154. doi: 10.1016/j.ejphar.2017.06.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejphar.2017.06.017</ArticleId><ArticleId IdType="pubmed">28623000</ArticleId></ArticleIdList></Reference><Reference><Citation>Tahmasebi S., Qasim M.T., Krivenkova M.V., Zekiy A.O., Thangavelu L., Aravindhan S., Izadi M., Jadidi-Niaragh F., Ghaebi M., Aslani S., et al. The effects of oxygen-ozone therapy on regulatory T-cell responses in multiple sclerosis patients. Cell Biol. Int. 2021;45:1498&#x2013;1509. doi: 10.1002/cbin.11589.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cbin.11589</ArticleId><ArticleId IdType="pubmed">33724614</ArticleId></ArticleIdList></Reference><Reference><Citation>Pfohl S.R., Halicek M.T., Mitchell C.S. Characterization of the Contribution of Genetic Background and Gender to Disease Progression in the SOD1 G93A Mouse Model of Amyotrophic Lateral Sclerosis: A Meta-Analysis. J. Neuromuscul. Dis. 2015;2:137&#x2013;150. doi: 10.3233/JND-140068.</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JND-140068</ArticleId><ArticleId IdType="pmc">PMC4652798</ArticleId><ArticleId IdType="pubmed">26594635</ArticleId></ArticleIdList></Reference><Reference><Citation>Jaarsma D. Swelling and vacuolisation of mitochondria in transgenic SOD1-ALS mice: A consequence of supranormal SOD1 expression? Mitochondrion. 2006;6:48&#x2013;49. doi: 10.1016/j.mito.2005.10.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mito.2005.10.005</ArticleId><ArticleId IdType="pubmed">16410057</ArticleId></ArticleIdList></Reference><Reference><Citation>Higgins C.M., Jung C., Xu Z. ALS-associated mutant SOD1G93A causes mitochondrial vacuolation by expansion of the intermembrane space and by involvement of SOD1 aggregation and peroxisomes. BMC Neurosci. 2003;4:16. doi: 10.1186/1471-2202-4-16.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2202-4-16</ArticleId><ArticleId IdType="pmc">PMC169170</ArticleId><ArticleId IdType="pubmed">12864925</ArticleId></ArticleIdList></Reference><Reference><Citation>Jaarsma D., Rognoni F., van Duijn W., Verspaget H.W., Haasdijk E.D., Holstege J.C. CuZn superoxide dismutase (SOD1) accumulates in vacuolated mitochondria in transgenic mice expressing amyotrophic lateral sclerosis-linked SOD1 mutations. Acta Neuropathol. 2001;102:293&#x2013;305. doi: 10.1007/s004010100399.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s004010100399</ArticleId><ArticleId IdType="pubmed">11603803</ArticleId></ArticleIdList></Reference><Reference><Citation>Ringer C., Weihe E., Sch&#xfc;tz B. SOD1G93A Mutant Mice Develop a Neuroinflammation-Independent Dendropathy in Excitatory Neuronal Subsets of the Olfactory Bulb and Retina. J. Neuropathol. Exp. Neurol. 2017;76:769&#x2013;778. doi: 10.1093/jnen/nlx057.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jnen/nlx057</ArticleId><ArticleId IdType="pubmed">28859334</ArticleId></ArticleIdList></Reference><Reference><Citation>Pryor W.A., Squadrito G.L., Friedman M. The cascade mechanism to explain ozone toxicity: The role of lipid ozonation products. Free Radic. Biol. Med. 1995;19:935&#x2013;941. doi: 10.1016/0891-5849(95)02033-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0891-5849(95)02033-7</ArticleId><ArticleId IdType="pubmed">8582671</ArticleId></ArticleIdList></Reference><Reference><Citation>Sagai M., Bocci V. Mechanisms of Action Involved in Ozone Therapy: Is healing induced via a mild oxidative stress? Med. Gas Res. 2011;1:29. doi: 10.1186/2045-9912-1-29.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/2045-9912-1-29</ArticleId><ArticleId IdType="pmc">PMC3298518</ArticleId><ArticleId IdType="pubmed">22185664</ArticleId></ArticleIdList></Reference><Reference><Citation>Mart&#xed;nez-S&#xe1;nchez G., Al-Dalain S.M., Men&#xe9;ndez S., Re L., Giuliani A., Candelario-Jalil E., Alvarez H., Fern&#xe1;ndez-Montequ&#xed;n J.I., Le&#xf3;n O.S. Therapeutic efficacy of ozone in patients with diabetic foot. Eur. J. Pharmacol. 2005;523:151&#x2013;161. doi: 10.1016/j.ejphar.2005.08.020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejphar.2005.08.020</ArticleId><ArticleId IdType="pubmed">16198334</ArticleId></ArticleIdList></Reference><Reference><Citation>Re L., Mawsouf M.N., Men&#xe9;ndez S., Le&#xf3;n O.S., S&#xe1;nchez G.M., Hern&#xe1;ndez F. Ozone therapy: Clinical and basic evidence of its therapeutic potential. Arch. Med. Res. 2008;39:17&#x2013;26. doi: 10.1016/j.arcmed.2007.07.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.arcmed.2007.07.005</ArticleId><ArticleId IdType="pubmed">18067991</ArticleId></ArticleIdList></Reference><Reference><Citation>Re L., Mart&#xed;nez-S&#xe1;nchez G., Bordicchia M., Malcangi G., Pocognoli A., Morales-Segura M.A., Rothchild J., Rojas A. Is ozone pre-conditioning effect linked to Nrf2/EpRE activation pathway in vivo? A preliminary result. Eur. J. Pharmacol. 2014;742:158&#x2013;162. doi: 10.1016/j.ejphar.2014.08.029.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejphar.2014.08.029</ArticleId><ArticleId IdType="pubmed">25218903</ArticleId></ArticleIdList></Reference><Reference><Citation>Ludolph A.C., Bendotti C., Blaugrund E., Chio A., Greensmith L., Loeffler J.P., Mead R., Niessen H.G., Petri S., Pradat P.F., et al. Guidelines for preclinical animal research in ALS/MND: A consensus meeting. Amyotroph. Lateral Scler. 2010;11:38&#x2013;45. doi: 10.3109/17482960903545334.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/17482960903545334</ArticleId><ArticleId IdType="pubmed">20184514</ArticleId></ArticleIdList></Reference><Reference><Citation>Benatar M. Lost in translation: Treatment trials in the SOD1 mouse and in human ALS. Neurobiol. Dis. 2007;26:1&#x2013;13. doi: 10.1016/j.nbd.2006.12.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2006.12.015</ArticleId><ArticleId IdType="pubmed">17300945</ArticleId></ArticleIdList></Reference><Reference><Citation>Schulz S., H&#xe4;ussler U., Mandic R., Heverhagen J.T., Neubauer A., D&#xfc;nne A.A., Werner J.A., Weihe E., Bette M. Treatment with ozone/oxygen-pneumoperitoneum results in complete remission of rabbit squamous cell carcinomas. Int. J. Cancer. 2008;122:2360&#x2013;2367. doi: 10.1002/ijc.23382.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ijc.23382</ArticleId><ArticleId IdType="pubmed">18224691</ArticleId></ArticleIdList></Reference><Reference><Citation>Bette M., N&#xfc;sing R.M., Mutters R., Zamora Z.B., Menendez S., Schulz S. Efficiency of tazobactam/piperacillin in lethal peritonitis is enhanced after preconditioning of rats with O3/O2-pneumoperitoneum. Shock. 2006;25:23&#x2013;29. doi: 10.1097/01.shk.0000187983.56030.dd.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.shk.0000187983.56030.dd</ArticleId><ArticleId IdType="pubmed">16369182</ArticleId></ArticleIdList></Reference><Reference><Citation>Bette M., Springmann V., Rossmann A., Weihe E., Sch&#xfc;tz B. Evidence for the absence of visceral pain in C57BL6/N mice subjected to therapeutically relevant O3/O2-pneumoperitoneum. Lab. Anim. 2017;51:17&#x2013;23. doi: 10.1177/0023677216636832.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0023677216636832</ArticleId><ArticleId IdType="pubmed">26946118</ArticleId></ArticleIdList></Reference><Reference><Citation>Ringer C., Weihe E., Schutz B. Calcitonin gene-related peptide expression levels predict motor neuron vulnerability in the superoxide dismutase 1-G93A mouse model of amyotrophic lateral sclerosis. Neurobiol. Dis. 2012;45:547&#x2013;554. doi: 10.1016/j.nbd.2011.09.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2011.09.011</ArticleId><ArticleId IdType="pubmed">21964254</ArticleId></ArticleIdList></Reference><Reference><Citation>Haenggeli C., Kato A.C. Differential vulnerability of cranial motoneurons in mouse models with motor neuron degeneration. Neurosci. Lett. 2002;335:39&#x2013;43. doi: 10.1016/S0304-3940(02)01140-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0304-3940(02)01140-0</ArticleId><ArticleId IdType="pubmed">12457737</ArticleId></ArticleIdList></Reference><Reference><Citation>Menon P., Vucic S. The Upper Motor Neuron-Improved Knowledge from ALS and Related Clinical Disorders. Brain Sci. 2021;11:958. doi: 10.3390/brainsci11080958.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/brainsci11080958</ArticleId><ArticleId IdType="pmc">PMC8392624</ArticleId><ArticleId IdType="pubmed">34439577</ArticleId></ArticleIdList></Reference><Reference><Citation>Marques C., Burg T., Scekic-Zahirovic J., Fischer M., Rouaux C. Upper and Lower Motor Neuron Degenerations Are Somatotopically Related and Temporally Ordered in the sod1 mouse model of amyotrophic lateral sclerosis. Brain Sci. 2021;11:369. doi: 10.3390/brainsci11030369.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/brainsci11030369</ArticleId><ArticleId IdType="pmc">PMC7998935</ArticleId><ArticleId IdType="pubmed">33805792</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu Z., Jung C., Higgins C., Levine J., Kong J. Mitochondrial degeneration in amyotrophic lateral sclerosis. J. Bioenerg. Biomembr. 2004;36:395&#x2013;399. doi: 10.1023/B:JOBB.0000041774.12654.e1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1023/B:JOBB.0000041774.12654.e1</ArticleId><ArticleId IdType="pubmed">15377878</ArticleId></ArticleIdList></Reference><Reference><Citation>Argueti-Ostrovsky S., Alfahel L., Kahn J., Israelson A. All Roads Lead to Rome: Different Molecular Players Converge to Common Toxic Pathways in Neurodegeneration. Cells. 2021;10:2438. doi: 10.3390/cells10092438.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells10092438</ArticleId><ArticleId IdType="pmc">PMC8468417</ArticleId><ArticleId IdType="pubmed">34572087</ArticleId></ArticleIdList></Reference><Reference><Citation>Parakh S., Atkin J.D. Protein folding alterations in amyotrophic lateral sclerosis. Brain Res. 2016;1648:633&#x2013;649. doi: 10.1016/j.brainres.2016.04.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.brainres.2016.04.010</ArticleId><ArticleId IdType="pubmed">27064076</ArticleId></ArticleIdList></Reference><Reference><Citation>Angenstein F., Niessen H.G., Goldschmidt J., Vielhaber S., Ludolph A.C., Scheich H. Age-dependent changes in MRI of motor brain stem nuclei in a mouse model of ALS. Neuroreport. 2004;15:2271&#x2013;2274. doi: 10.1097/00001756-200410050-00026.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00001756-200410050-00026</ArticleId><ArticleId IdType="pubmed">15371748</ArticleId></ArticleIdList></Reference><Reference><Citation>Hanisch U.K., Kettenmann H. Microglia: Active sensor and versatile effector cells in the normal and pathologic brain. Nat. Neurosci. 2007;10:1387&#x2013;1394. doi: 10.1038/nn1997.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn1997</ArticleId><ArticleId IdType="pubmed">17965659</ArticleId></ArticleIdList></Reference><Reference><Citation>Clarke B.E., Patani R. The microglial component of amyotrophic lateral sclerosis. Brain. 2020;143:3526&#x2013;3539. doi: 10.1093/brain/awaa309.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awaa309</ArticleId><ArticleId IdType="pmc">PMC7805793</ArticleId><ArticleId IdType="pubmed">33427296</ArticleId></ArticleIdList></Reference><Reference><Citation>Schwartz M., Shechter R. Systemic inflammatory cells fight off neurodegenerative disease. Nat. Rev. Neurol. 2010;6:405&#x2013;410. doi: 10.1038/nrneurol.2010.71.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrneurol.2010.71</ArticleId><ArticleId IdType="pubmed">20531383</ArticleId></ArticleIdList></Reference><Reference><Citation>Beers D.R., Henkel J.S., Zhao W., Wang J., Appel S.H. CD4+ T cells support glial neuroprotection, slow disease progression, and modify glial morphology in an animal model of inherited ALS. Proc. Natl. Acad. Sci. USA. 2008;105:15558&#x2013;15563. doi: 10.1073/pnas.0807419105.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0807419105</ArticleId><ArticleId IdType="pmc">PMC2547419</ArticleId><ArticleId IdType="pubmed">18809917</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiu I.M., Chen A., Zheng Y., Kosaras B., Tsiftsoglou S.A., Vartanian T.K., Brown R.H., Carroll M.C. T lymphocytes potentiate endogenous neuroprotective inflammation in a mouse model of ALS. Proc. Natl. Acad. Sci. USA. 2008;105:17913&#x2013;17918. doi: 10.1073/pnas.0804610105.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0804610105</ArticleId><ArticleId IdType="pmc">PMC2581614</ArticleId><ArticleId IdType="pubmed">18997009</ArticleId></ArticleIdList></Reference><Reference><Citation>Banerjee R., Mosley R.L., Reynolds A.D., Dhar A., Jackson-Lewis V., Gordon P.H., Przedborski S., Gendelman H.E. Adaptive immune neuroprotection in G93A-SOD1 amyotrophic lateral sclerosis mice. PLoS ONE. 2008;3:e2740. doi: 10.1371/journal.pone.0002740.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0002740</ArticleId><ArticleId IdType="pmc">PMC2481277</ArticleId><ArticleId IdType="pubmed">18648532</ArticleId></ArticleIdList></Reference><Reference><Citation>Staats K.A., Borchelt D.R., Tansey M.G., Wymer J. Blood-based biomarkers of inflammation in amyotrophic lateral sclerosis. Mol. Neurodegener. 2022;17:11. doi: 10.1186/s13024-022-00515-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13024-022-00515-1</ArticleId><ArticleId IdType="pmc">PMC8785449</ArticleId><ArticleId IdType="pubmed">35073950</ArticleId></ArticleIdList></Reference><Reference><Citation>Kang J., Rivest S. MyD88-deficient bone marrow cells accelerate onset and reduce survival in a mouse model of amyotrophic lateral sclerosis. J. Cell Biol. 2007;179:1219&#x2013;1230. doi: 10.1083/jcb.200705046.</Citation><ArticleIdList><ArticleId IdType="doi">10.1083/jcb.200705046</ArticleId><ArticleId IdType="pmc">PMC2140021</ArticleId><ArticleId IdType="pubmed">18086918</ArticleId></ArticleIdList></Reference><Reference><Citation>Gasco S., Zaragoza P., Garc&#xed;a-Redondo A., Calvo A.C., Osta R. Inflammatory and non-inflammatory monocytes as novel prognostic biomarkers of survival in SOD1G93A mouse model of Amyotrophic Lateral Sclerosis. PLoS ONE. 2017;12:e0184626. doi: 10.1371/journal.pone.0184626.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0184626</ArticleId><ArticleId IdType="pmc">PMC5591000</ArticleId><ArticleId IdType="pubmed">28886177</ArticleId></ArticleIdList></Reference><Reference><Citation>Scassellati C., Galoforo A.C., Esposito C., Ciani M., Ricevuti G., Bonvicini C. Promising Intervention Approaches to Potentially Resolve Neuroinflammation and Steroid Hormones Alterations in Alzheimer&#x2019;s Disease and Its Neuropsychiatric Symptoms. Aging. Dis. 2021;12:1337&#x2013;1357. doi: 10.14336/AD.2021.0122.</Citation><ArticleIdList><ArticleId IdType="doi">10.14336/AD.2021.0122</ArticleId><ArticleId IdType="pmc">PMC8279527</ArticleId><ArticleId IdType="pubmed">34341712</ArticleId></ArticleIdList></Reference><Reference><Citation>Leitner M., Menzies S., Lutz C. Working with ALS mice. Guidelines for preclinical testing and colony management. Jackson Lab. 2009</Citation></Reference><Reference><Citation>Weydt P., Hong S.Y., Kliot M., M&#xf6;ller T. Assessing disease onset and progression in the SOD1 mouse model of ALS. Neuroreport. 2003;14:1051&#x2013;1054. doi: 10.1097/01.wnr.0000073685.00308.89.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.wnr.0000073685.00308.89</ArticleId><ArticleId IdType="pubmed">12802201</ArticleId></ArticleIdList></Reference><Reference><Citation>Ringer C., Tune S., Bertoune M.A., Schwarzbach H., Tsujikawa K., Weihe E., Sch&#xfc;tz B. Disruption of calcitonin gene-related peptide signaling accelerates muscle denervation and dampens cytotoxic neuroinflammation in SOD1 mutant mice. Cell Mol. Life Sci. 2017;74:339&#x2013;358. doi: 10.1007/s00018-016-2337-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00018-016-2337-4</ArticleId><ArticleId IdType="pubmed">27554772</ArticleId></ArticleIdList></Reference><Reference><Citation>Sever B., Ciftci H., DeMirci H., Sever H., Ocak F., Yulug B., Tateishi H., Tateishi T., Otsuka M., Fujita M., et al. Comprehensive Research on Past and Future Therapeutic Strategies Devoted to Treatment of Amyotrophic Lateral Sclerosis. Int. J. Mol. Sci. 2022;23:2400. doi: 10.3390/ijms23052400.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms23052400</ArticleId><ArticleId IdType="pmc">PMC8910198</ArticleId><ArticleId IdType="pubmed">35269543</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>